secwatch.observer — SEC 8-K summary
======================================

Issuer:     PepGen Inc. (PEPG)
CIK:        0001835597
Form:       8-K
Filed at:   2025-11-12T23:59:59+00:00
Accession:  0001193125-25-276019
Event type: earnings
Sentiment:  positive
Materiality: 0.75
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

PepGen reports Q3 net loss of $18.0M; 53.7% splicing correction in DM1 Phase 1
------------------------------------------------------------------------------

- FREEDOM-DM1 15 mg/kg showed mean splicing correction of 53.7%, highest reported in DM1 patients.
- All patients in FREEDOM2 5 mg/kg cohort enrolled; topline data expected Q1 2026.
- Closed $115M public offering in Sept 2025; cash runway extended into H2 2027.
- Net loss $18.0M ($0.52/sh) vs $21.4M ($0.66/sh) in Q3 2024; cash $163.7M at Sept 30.
- R&D expense $13.4M down from $17.7M YoY; G&A flat at $5.2M.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1835597/000119312525276019/0001193125-25-276019-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1835597/000119312525276019/pepg-20251112.htm
  HTML page:      https://secwatch.observer/filing/0001193125-25-276019

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer